Innovation in GLP-1 to support Novo Nordisk's leading position

11 November 2022
novo_nordisk_big

Diabetes giant Novo Nordisk (NOV: N) looks set to maintain its dominant position in type 2 diabetes, despite recent supply issues affecting its glucagon-like peptide-1 (GLP-1) franchise.

Research from industry analyst GlobalData suggests that the launch of the firm’s oral GLP-1 agonist Rybelsus (semaglutide) could play a role in defending against rivals.

While sales have only increased slowly, the patient-friendly mode of administration provides a unique selling point in a congested market, adding to the firm’s established market share for the injectable Ozempic (semaglutide).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical